Hydrocortisone Activase Pharmaceuticals

Hydrocortisone Activase Pharmaceuticals is a corticosteroid medication whose active ingredient is hydrocortisone. It is supplied in an oral dosage form, with strength and specific formulation not disclosed, and is marketed in the European Union. As a glucocorticoid agonist, it exerts anti‑inflammatory and immunosuppressive actions. It is classified under ATC code H02AB02 and is intended for use in settings.

Hydrocortisone Activase Pharmaceuticals is indicated for several medical conditions where glucocorticoid therapy is required to replace deficient hormones or suppress excessive inflammation.

- Replacement therapy for primary or secondary adrenal insufficiency, providing necessary glucocorticoid support. - Management of acute inflammatory episodes such as severe allergic reactions, including angioedema and anaphylaxis. - Treatment of chronic inflammatory skin disorders including eczema, psoriasis, and contact dermatitis. - Adjunctive therapy for certain autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus. - Short‑term control of inflammation in respiratory conditions like asthma or COPD, and in musculoskeletal disorders such as bursitis. - Temporary reduction of swelling and pain following minor surgical procedures or dental extractions.

Adverse reactions to hydrocortisone can vary in frequency and severity.

Common: - Mild skin irritation or localized itching at the site of application (if topical) or gastrointestinal discomfort when taken orally. - Transient increase in blood glucose levels, especially in patients with diabetes. - Fluid retention leading to mild swelling of the ankles or face. - Insomnia or mood changes such as irritability. - Weight gain or increased appetite, often observed with systemic therapy. - Facial rounding (moon face) and redistribution of body fat.

Serious: - Suppression of the hypothalamic‑pituitary‑adrenal (HPA) axis causing adrenal insufficiency. - Severe infections due to immunosuppression, including opportunistic fungal or bacterial infections. - Osteoporosis or increased risk of fractures with prolonged use. - Severe hypertension or cardiovascular events in predisposed individuals.

When prescribing or using hydrocortisone, clinicians should carefully consider several precautionary measures to minimize risks.

- Evaluate adrenal function before initiating therapy and monitor for signs of suppression. - Use the lowest effective dose for the shortest duration necessary. - Caution in patients with uncontrolled diabetes, hypertension, or peptic ulcer disease. - Avoid abrupt discontinuation; taper gradually to prevent adrenal crisis. - Assess bone health periodically in long‑term users, especially postmenopausal women. - Consider alternative therapies in pregnant or nursing women due to limited safety data.

Hydrocortisone may interact with other medicines, altering its efficacy or increasing the likelihood of adverse effects.

Avoid: - Concurrent use of potent CYP3A4 inducers such as rifampin, which can reduce hydrocortisone plasma concentrations. - Co‑administration with systemic antifungals like ketoconazole that inhibit glucocorticoid metabolism, potentially raising drug levels.

Use with caution: - Non‑steroidal anti‑inflammatory drugs (NSAIDs) may increase the risk of gastrointestinal bleeding. - Anticoagulants (e.g., warfarin) may have altered effects due to hydrocortisone‑induced changes in clotting factor synthesis. - Vaccines, especially live attenuated ones, may have reduced efficacy or increased risk of infection. - Diuretics may enhance fluid loss and electrolyte disturbances.